目的:评价动脉内输注亚胺培南/西司他丁钠(IPM/CS)治疗疼痛性指间关节骨关节炎(OA)的有效性和安全性。
方法:回顾性评估58例接受动脉内IPM/CS输注的指间关节OA患者。通过经皮腕部动脉通路进行动脉内输注。数字评级量表(NRS),手部骨关节炎的功能指数(FIHOA),在1,3,6,12和18个月的间隔评估患者的整体变化印象(PGIC)量表.基于PGIC评估临床成功。
结果:所有患者在治疗后随访至少6个月。其中,30例和6例患者随访12个月和18个月,分别。没有发生严重或危及生命的不良事件。基线时平均NRS为6.0±1.4,在治疗后1、3和6个月,显着降低至2.8±1.4、2.2±1.9和2.4±1.9,(均P<0.001)。12个月和18个月的平均NRS分别为2.8±1.7和2.9±1.9,分别,剩下的病人。平均FIHOA评分从基线时的9.8±5.0显著降低至3个月时的4.1±3.5(P<0.001)。其余30例患者在12个月时的平均FIHOA评分为4.5±3.3。基于PGIC的1、3、6、12和18个月的临床成功率为62.1%,77.6%,70.7%,63.4%,50.0%,分别。
结论:动脉内IPM/CS输注是指间关节OA的潜在治疗选择。
To evaluate the effectiveness and safety of intra-arterial imipenem/cilastatin sodium (IPM/CS) infusion for painful interphalangeal joint osteoarthritis (OA).
Fifty-eight patients with interphalangeal joint OA who underwent intra-arterial IPM/CS infusion were retrospectively evaluated. Intra-arterial infusions were performed via percutaneous wrist arterial access. The Numerical Rating Scale (NRS), Functional Index for Hand Osteoarthritis (FIHOA), and Patient Global Impression of Change (PGIC) scale scores were assessed at intervals of 1, 3, 6, 12, and 18 months. Clinical success was evaluated based on PGIC.
All patients were followed up for at least 6 months after treatment. Of them, 30 and 6 patients were followed up for 12 and 18 months, respectively. No severe or life-threatening adverse events were encountered. The mean NRS score was 6.0 ± 1.4 at baseline, which significantly decreased to 2.8 ± 1.4, 2.2 ± 1.9, and 2.4 ± 1.9 at 1, 3, and 6 months after treatment, respectively (all P < .001). The mean NRS scores were 2.8 ± 1.7 and 2.9 ± 1.9 at 12 and 18 months, respectively, in the remaining patients. The mean FIHOA score significantly decreased from 9.8 ± 5.0 at the baseline to 4.1 ± 3.5 at 3 months (P < .001). The mean FIHOA score was 4.5 ± 3.3 at 12 months in the remaining 30 patients. The clinical success rates based on PGIC at 1, 3, 6, 12, and 18 months were 62.1%, 77.6%, 70.7%, 63.4%, and 50.0%, respectively.
Intra-arterial IPM/CS infusion is a potential treatment option for interphalangeal joint OA refractory to medical management.